Plain-English translation of NCT07517263 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who completed an earlier trial testing a medication called pelacarsen. You would continue receiving pelacarsen as a monthly injection to help lower lipoprotein(a), a substance in your blood linked to heart disease. The main goal is to make sure the medication remains safe and well-tolerated when used long-term.
Lipoprotein(a) is a genetic risk factor for heart disease that's hard to treat with standard medications. This study exists to gather important information about whether this new medication can be given safely for many months or years, and whether people continue to benefit from it without developing serious side effects.
You likely qualify if…
You likely don't qualify if…
You would continue receiving pelacarsen as a monthly injection at study visits. The study is open-label, meaning both you and your doctor know you're receiving the medication. Researchers will monitor your safety and tolerability through regular check-ins, blood work, and assessments to ensure the long-term treatment remains safe and effective for your heart condition.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States